Status:

COMPLETED

Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Lead Sponsor:

University of Florida

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

Prasugrel has shown to be superior to clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic events. Prasugrel is approved in patients with ST-elevation myocardial infarction (STEMI) und...

Detailed Description

Dual antiplatelet therapy consisting of aspirin and a P2Y12 receptor antagonist is the cornerstone of treatment for prevention of thrombotic events in patients with acute coronary syndromes (ACS). Pra...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Patients with ST-elevation myocardial infarction undergoing primary PCI
  • Age between 18 and 75 years old
  • Exclusion criteria:
  • Age \>75 years
  • Weight \<60 Kg
  • On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 7 days
  • Known allergies to aspirin or prasugrel
  • Considered at high risk for bleeding
  • History of ischemic or hemorrhagic stroke or transient ischemic attack
  • On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban)
  • Treatment with IIb/IIIa glycoprotein inhibitors
  • Fibrinolytics within 24 hours
  • Known blood dyscrasia or bleeding diathesis
  • Known platelet count \<80x106/mL
  • Known hemoglobin \<10 g/dL
  • Active bleeding
  • Hemodynamic instability
  • Known creatinine clearance \<30 mL/minute
  • Known severe hepatic dysfunction
  • Pregnant females\*
  • Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

Exclusion

    Key Trial Info

    Start Date :

    October 1 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2015

    Estimated Enrollment :

    52 Patients enrolled

    Trial Details

    Trial ID

    NCT02212028

    Start Date

    October 1 2014

    End Date

    August 1 2015

    Last Update

    December 28 2016

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Florida

    Jacksonville, Florida, United States, 32209

    Pharmacological Effects of Crushing Prasugrel in STEMI Patients | DecenTrialz